Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields + TMZ + Tislelizumab in Newly Diagnosed Glioblastoma
NCT06353360Phase 2Recruiting
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology
- Start
- Apr 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in glioblastoma (GBM), sponsored by Jiangsu Healthy Life Innovation Medical Technology. Primary endpoint: Progression-Free Survival at 18 months. Started Apr 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06353360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353360.